TY - JOUR AB - The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). A total of 114 patients with HL treated between 2004 and 2013 were enrolled for evaluation. The association of variables with overall survival (OS) and progression‑free survival (PFS) was analysed using univariate and multivariate Cox proportional hazards models. The median age of patients was 39 years, and the majority were male and had stage IV disease. A total of 54 patients received ABVD and 60 received BEACOPP chemotherapy with 24 and four deaths, respectively. Patients in the BEACOPP group were significantly younger with lower Charlson comorbidity index (CCI) and better performance status in comparison with the ABVD group, making the comparison of groups not possible. In the ABVD group, RDI was not significantly associated with OS (P=0.590) or PFS (P=0.354) in a multivariate model where age was controlled. The low number of events prevented this analysis in the BEACOPP group. The age of patients was strongly associated with both OS and PFS; all statistically significant predictors for OS and PFS from univariate analyses (chemotherapy regimen, CCI, RDI, performance status) lost their effect in multivariate analyses where age was controlled. Based on these observations, it was concluded that RDI was not associated with OS or PFS after age is controlled, neither in all patients combined nor in the ABVD group. AD - Pharmacy Department, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia The Department of Lymphoma Treatment, Division of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia Department of Molecular Diagnostics, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia AU - Rožman,Samo AU - Novaković,Barbara,Jezeršek AU - Gorenjec,Nina,Ružić AU - Novaković,Srdjan AU - Rožman,Samo AU - Novaković,Barbara,Jezeršek AU - Gorenjec,Nina,Ružić AU - Novaković,Srdjan DA - 2022/09/01 DO - 10.3892/ol.2022.13440 IS - 3 JO - Oncol Lett KW - Hodgkin lymphoma relative dose intensity primary treatment chemotherapy outcome PY - 2022 SN - 1792-1074 1792-1082 SP - 320 ST - Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma T2 - Oncology Letters TI - Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma UR - https://doi.org/10.3892/ol.2022.13440 VL - 24 ER -